Marktanalyse - Liver Failure (Hepatic Insufficiency) - Pipeline Review, H2 2016

Global Markets Direct
12.2016
89 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Liver Failure (Hepatic Insufficiency) - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Failure (Hepatic Insufficiency) — Pipeline Review, H2 2016, provides an overview of the Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline landscape.

Liver failure is severe deterioration of liver function. Liver failure occurs when a large portion of the liver is damaged due to any type of liver disorder. Symptoms may include jaundice, tendency to bruise or bleed easily, ascites, impaired brain function (encephalopathy), poor weight gain and growth, fatigue, weakness, nausea and loss of appetite. Since these symptoms are associated with a host of other conditions, it may take some time before the correct diagnosis is made. As liver failure worsens, people may experience disorientation and drowsiness. At this stage, there is a risk of coma and death.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Failure (Hepatic Insufficiency) — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Liver Failure (Hepatic Insufficiency) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Failure (Hepatic Insufficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 1, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Failure (Hepatic Insufficiency) (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Liver Failure (Hepatic Insufficiency) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Liver Failure (Hepatic Insufficiency) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Liver Failure (Hepatic Insufficiency) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Liver Failure (Hepatic Insufficiency) (Gastrointestinal)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Liver Failure (Hepatic Insufficiency) (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Liver Failure (Hepatic Insufficiency) Overview 8

Therapeutics Development 9

Pipeline Products for Liver Failure (Hepatic Insufficiency) - Overview 9

Pipeline Products for Liver Failure (Hepatic Insufficiency) - Comparative Analysis 10

Liver Failure (Hepatic Insufficiency) - Therapeutics under Development by Companies 11

Liver Failure (Hepatic Insufficiency) - Therapeutics under Investigation by Universities/Institutes 12

Liver Failure (Hepatic Insufficiency) - Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Unknown Stage Products 16

Liver Failure (Hepatic Insufficiency) - Products under Development by Companies 17

Liver Failure (Hepatic Insufficiency) - Products under Investigation by Universities/Institutes 18

Liver Failure (Hepatic Insufficiency) - Companies Involved in Therapeutics Development 19

Alfact Innovation 19

BioLineRx Ltd 20

Cell2B Advanced Therapeutics SA 21

Conatus Pharmaceuticals Inc 22

Immune Pharmaceuticals Inc 23

Mina Therapeutics Ltd 24

Mylan NV 25

Ocera Therapeutics Inc 26

PledPharma AB 27

Promethera Biosciences SA 28

Silence Therapeutics Plc 29

TGV-Laboratories 30

Unicyte AG 31

Ventria Bioscience 32

Liver Failure (Hepatic Insufficiency) - Therapeutics Assessment 33

Assessment by Monotherapy Products 33

Assessment by Target 34

Assessment by Mechanism of Action 36

Assessment by Route of Administration 38

Assessment by Molecule Type 40

Drug Profiles 42

ALF-5755 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Antisense RNAi Oligonucleotide for Liver Diseases - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

BL-1220 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Cell Therapy for Liver Failure - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

emricasan - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

F-573 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Hep-114 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

HepaStem - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

ImmuneSafe - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

MTL-CEBPA - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

Oligonucleotide for Liver Failure - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

ornithine phenylacetate - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

PP-100 - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

Recombinant Protein to Inhibit JNK for Liver Failure - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

RNAi Oligonucleotides to Inhibit MAP Kinase 4 for Liver Failure - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

silibinin - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

Small Molecules to Inhibit JNK for Type 2 Diabetes and Liver Failure - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

Stem Cell Therapy for Osteoarthritis, Diabetes Mellitus, Acute Liver Failure and Neurodegenerative Diseases - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

Stem Cell Therapy for Type 1 Diabetes, Urea Cycle Disorders and Acute Liver Failure - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

VEN-100 - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

Liver Failure (Hepatic Insufficiency) - Dormant Projects 76

Liver Failure (Hepatic Insufficiency) - Discontinued Products 77

Liver Failure (Hepatic Insufficiency) - Product Development Milestones 78

Featured News & Press Releases 78

Oct 24, 2016: Ocera Therapeutics Announces Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2016 78

Sep 21, 2016: Ocera Announces Enrollment Completion From Phase 2a NIH-Sponsored Study of OCR-002 in the Treatment of Patients with Acute Liver Failure 78

Nov 19, 2015: Marina Biotech Reports pre-clinical data on its MTL-CEBPA at the 2015 American Association for the Study of Liver Diseases 78

Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting 79

Oct 05, 2015: Ocera Therapeutics Highlights OCR-002 Data to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases 80

Jan 08, 2015: Conatus Announces Top-Line Results From ACLF and Organ Impairment Clinical Trials of Emricasan 81

Jan 05, 2015: Conatus to Report Top-line Results From ACLF and Organ Impairment Clinical Trials of Emricasan 83

Nov 02, 2013: Conatus Pharmaceuticals Presents Data Demonstrating Emricasan's Safety Profile at the AASLD Liver Meeting 83

Apr 11, 2013: Gene inhibition helps to improve liver regeneration 84

Apr 02, 2013: ALF-5755 phase II completion 85

Nov 08, 2012: Ocera Therapeutics Enrolls First Patient In Phase IIa Study Of OCR-002 In Treatment Of Patients With Acute Liver Injury 85

Aug 03, 2012: MDC Researchers Develop New Approach to Treat Acute Liver Failure 86

May 06, 2011: ALF-5755 phase II extends to Germany 87

May 05, 2011: Alfact Innovation Receives Orphan Drug Designation For ALF-5755 From FDA 87

Appendix 88

Methodology 88

Coverage 88

Secondary Research 88

Primary Research 88

Expert Panel Validation 88

Contact Us 88

Disclaimer 89





List of Tables

Number of Products under Development for Liver Failure (Hepatic Insufficiency), H2 2016 9

Number of Products under Development for Liver Failure (Hepatic Insufficiency) - Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Number of Products under Investigation by Universities/Institutes, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Clinical Stage Development, H2 2016 14

Comparative Analysis by Early Stage Development, H2 2016 15

Comparative Analysis by Unknown Stage Development, H2 2016 16

Products under Development by Companies, H2 2016 17

Products under Investigation by Universities/Institutes, H2 2016 18

Liver Failure (Hepatic Insufficiency) - Pipeline by Alfact Innovation, H2 2016 19

Liver Failure (Hepatic Insufficiency) - Pipeline by BioLineRx Ltd, H2 2016 20

Liver Failure (Hepatic Insufficiency) - Pipeline by Cell2B Advanced Therapeutics SA, H2 2016 21

Liver Failure (Hepatic Insufficiency) - Pipeline by Conatus Pharmaceuticals Inc, H2 2016 22

Liver Failure (Hepatic Insufficiency) - Pipeline by Immune Pharmaceuticals Inc, H2 2016 23

Liver Failure (Hepatic Insufficiency) - Pipeline by Mina Therapeutics Ltd, H2 2016 24

Liver Failure (Hepatic Insufficiency) - Pipeline by Mylan NV, H2 2016 25

Liver Failure (Hepatic Insufficiency) - Pipeline by Ocera Therapeutics Inc, H2 2016 26

Liver Failure (Hepatic Insufficiency) - Pipeline by PledPharma AB, H2 2016 27

Liver Failure (Hepatic Insufficiency) - Pipeline by Promethera Biosciences SA, H2 2016 28

Liver Failure (Hepatic Insufficiency) - Pipeline by Silence Therapeutics Plc, H2 2016 29

Liver Failure (Hepatic Insufficiency) - Pipeline by TGV-Laboratories, H2 2016 30

Liver Failure (Hepatic Insufficiency) - Pipeline by Unicyte AG, H2 2016 31

Liver Failure (Hepatic Insufficiency) - Pipeline by Ventria Bioscience, H2 2016 32

Assessment by Monotherapy Products, H2 2016 33

Number of Products by Stage and Target, H2 2016 35

Number of Products by Stage and Mechanism of Action, H2 2016 37

Number of Products by Stage and Route of Administration, H2 2016 39

Number of Products by Stage and Molecule Type, H2 2016 41

Liver Failure (Hepatic Insufficiency) - Dormant Projects, H2 2016 76

Liver Failure (Hepatic Insufficiency) - Discontinued Products, H2 2016 77





List of Figures

Number of Products under Development for Liver Failure (Hepatic Insufficiency), H2 2016 9

Number of Products under Development for Liver Failure (Hepatic Insufficiency) - Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 15

Assessment by Monotherapy Products, H2 2016 33

Number of Products by Top 10 Targets, H2 2016 34

Number of Products by Stage and Top 10 Targets, H2 2016 34

Number of Products by Top 10 Mechanism of Actions, H2 2016 36

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 36

Number of Products by Routes of Administration, H2 2016 38

Number of Products by Stage and Routes of Administration, H2 2016 38

Number of Products by Molecule Types, H2 2016 40

Number of Products by Stage and Molecule Types, H2 2016 40

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus